Sacubitril/Valsartan Sodium Tablets (Entresto) is an angiotensin receptor-neprilysin inhibitor (ARNI), which has created a new model for the treatment of chronic heart failure. Through its dual effects, this drug has shown significant advantages in improving the prognosis of patients with heart failure.

What Are the Indications of Sacubitril/Valsartan Sodium Tablets (Entresto)?

Treatment of Chronic Cardiac Insufficiency

All dosage forms (tablets: 50mg/100mg/200mg; granules: pediatric 12.5mg/31.25mg) are indicated for the treatment of chronic heart failure in adults and children.

Adult patients should use this drug on the basis of standard heart failure treatment regimens.

Indications for Hypertension Treatment

Only the 100mg and 200mg tablets are approved for the treatment of hypertension.

The 50mg tablets and all pediatric granules are not authorized for hypertension treatment.

Specifications and Characteristics of Sacubitril/Valsartan Sodium Tablets (Entresto)

50mg Tablets

Bluish-purple to white oval film-coated tablets, with a major diameter of approximately 13.1mm, a minor diameter of approximately 5.2mm, a thickness of approximately 3.6mm, and a mass of 0.208g.

The tablet surface is marked with the code "NVRLZ".

100mg Tablets

Pale yellow oval film-coated tablets with a score line, with a major diameter of approximately 13.1mm, a minor diameter of approximately 5.2mm, a thickness of approximately 3.7mm, and a mass of 0.208g. Marked with the code "L".

200mg Tablets

Pale reddish-white oval film-coated tablets, with a major diameter of approximately 15.1mm, a minor diameter of approximately 6.0mm, a thickness of approximately 5.4mm, and a mass of 0.412g. Marked with the code "NVRL11".

Pediatric 12.5mg Granules

White to pale yellow round small granules, with a diameter of approximately 2.0mm and a thickness of approximately 2.2mm.

The code is displayed as follows: the white cap is marked with "04", and the colorless and transparent body is marked with "NVR".

Pediatric 31.25mg Granules

White to pale yellow round small granules, with a diameter of approximately 2.0mm and a thickness of approximately 2.2mm.

The identification code is configured as follows: the yellow cap is marked with "10", and the colorless and transparent body is marked with "NVR".

Key Precautions for Sacubitril/Valsartan Sodium Tablets (Entresto)

Warnings for Contraindicated Populations

Patients with a history of allergy to any component of the drug.

Patients with a past history of angioedema.

Patients receiving combined medication with ACEIs (angiotensin-converting enzyme inhibitors).

Patients with severe hepatic impairment and pregnant women.

Important Drug Interactions

Combined use with aliskiren is prohibited in diabetic patients (except for refractory hypertension).

When used in combination with potassium preparations, the risk of hyperkalemia should be watched out for.

Medication for Special Populations

Patients with renal impairment need to adjust the dosage according to their eGFR (estimated glomerular filtration rate) values.

Elderly patients should have their initial dosage reduced as appropriate and undergo close monitoring.